Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2C18 | P33260 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15638722 | 0.81 | OXTR (0.38) | KDM4ENR3C2 | |
| SCHEMBL15638493 | 0.81 | ALDH1A1 (0.41) | CYP2C9CYP2C19CYP2C18LMNACYP3A4 | |
| SCHEMBL2557804 | 0.74 | MAPT (0.44) | POLBKDM4ELMNATDP1ALDH1A1 | |
| SCHEMBL5579308 | 0.72 | POLB (0.57) | POLBCYP2C9KDM4ECYP2C19CYP2C18 | |
| SCHEMBL7006506 | 0.69 | CYP2C9 (0.57) | POLBCYP2C9KDM4ECYP2C19CYP2C18 | |
| SCHEMBL8674209 | 0.68 | POLB (0.57) | POLBCYP2C9KDM4ECYP2C19CYP2C18 | |
| SCHEMBL17227421 | 0.68 | POLB (0.57) | POLBCYP2C9KDM4ECYP2C19CYP2C18 | |
| SCHEMBL255499 | 0.68 | POLB (0.57) | POLBCYP2C9KDM4ECYP2C19CYP2C18 | |
| SCHEMBL7082394 | 0.68 | POLB (0.57) | POLBCYP2C9KDM4ECYP2C19CYP2C18 | |
| SCHEMBL5318677 | 0.68 | POLB (0.57) | POLBCYP2C9KDM4ECYP2C19CYP2C18 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190084981-A1 | Bromodomain Inhibitors | ABBVIE INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10131657-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-9957263-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2903980-B1 | BENZIMIDAZOLES AS CNS ACTIVE AGENTS | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| EP-2602254-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-14 | — | — | EP | disclosed |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| EP-2602255-B1 | FUSED HETEROCYCLIC RING COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-26 | — | — | EP | disclosed |
| CN-104703981-B | As the benzimidazoles compound of CNS activity medicament | 霍夫曼-拉罗奇有限公司 | 2017-03-29 | — | — | CN | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-8354411-B2 | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | POLB 1658/4885CYP2C9 630/4885KDM4E 1514/4885 |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | POLB 1658/4885CYP2C9 630/4885KDM4E 1514/4885 |
| US-20190084981-A1 | Bromodomain Inhibitors | BRD4, BRD1, BRD3 | POLB 1896/4885CYP2C9 3955/4885KDM4E 749/4885 |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | POLB 1356/4885CYP2C9 637/4885KDM4E 1652/4885 |
| US-10131657-B2 | Bromodomain inhibitors | BRD1, BRD4, BRD3 | POLB 1800/4885CYP2C9 3812/4885KDM4E 834/4885 |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | POLB 1658/4885CYP2C9 630/4885KDM4E 1514/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | POLB 1658/4885CYP2C9 630/4885KDM4E 1514/4885 |
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | POLB 1587/4885CYP2C9 569/4885KDM4E 1502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.